GlassScriptPhysician profile
Ashley M Sankiewicz
NPI 1457807893
$3,923.28
in general payments reported to CMS, 2019-2025
36 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $718 · 2023: $523 · 2024: $1,002 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $377.85 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $336.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $290.38 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $206.92 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $200.54 | 2021-2025 | |
| Exact Sciences Corporation | $177.11 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $169.37 | 2022-2025 | Rexulti |
| Ucb, INC. | $118.54 | 2021-2023 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $108.88 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.57 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $80.57 | 2021-2024 | Veozah |
| Dexcom, INC. | $76.17 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.78 | 2022-2025 | Xifaxan |
| Amgen INC. | $64.13 | 2021-2025 | Evenity |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Sankiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.